VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
TLX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
TLXTelix Pharmaceuticals Limited
$8.86$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
TLX logo

Telix Pharmaceuticals Limited

TLX
NASDAQ · Oncology Biotech
$8.86
At close - Nov 17, 4:00 PM EST - USD
Market Cap$3B
P/E-427.8x
52W High$13.11
Volume247.71K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Radiopharmaceutical Growth Lagged by Operating Losses

Telix Pharmaceuticals is experiencing a re-acceleration in revenue growth, reaching 16.6% in 2026Q2, as its radiopharmaceutical portfolio gains commercial traction.

GrowthAccelerating
ProfitabilityStrained
ValuationExpensive
TechnicalsWeak
Explore valuation models
MARKET ACTION

TLX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

3/12 Beats

EPS beat 3 of last 12 quarters

02

Valuation risk

-1952% Peers

P/E is 1952% below peer median

03

Market leadership

RS 52 · Avg

Average momentum (RS Rating: 52)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Nov 19

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
TLX+16.21%
S&P 500 (^GSPC)+7.21%
1-Year Return
TLX-3.33%
S&P 500 (^GSPC)+10.03%
3-Year Return
TLX-41.55%
S&P 500 (^GSPC)+61.63%
5-Year Return
TLX-41.55%
S&P 500 (^GSPC)+55.52%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-428.0x
Forward P/E
72.9x
EV/EBITDA100th %ile
85.6x
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-428.0x
110.0x
0th· Low
EV/EBITDA
85.6x
73.5x
100th· High
Price/FCF
N/A
185.2x
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$1.03-88.4%
Base (Fair)$2.27-76.4%
Bull$2.85-67.8%
$1.03 Bear$2.27 Base$2.85 Bull
Current Market Price: $8.86
Trades at a 290.1% premium to Base DCF ($2.27)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$790M+0.8% YoY
Net income FY25
-$7M-114.0% YoY
Free cash flow FY25
-$54M-289.0% YoY
Operating margin FY25
2.2%-8.3 pts YoY
ROIC (FY25)2.2%
Avg ROIC 5Y55.2%
ROE (FY25)-1.4%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate3/12 (30%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 19, 2026
$0.11+140.3%
vs $0.04
$477M-0.5%
vs $480M
Q1 2026
Feb 19, 2026
-$0.01-135.4%
vs $0.03
$413M-1.2%
vs $418M
Q3 2025
Aug 20, 2025
-$0.01-105.1%
vs $0.13
$390M-0.0%
vs $390M
Q1 2025
Feb 20, 2025
$0.11+22.5%
vs $0.09
$267M+97.9%
vs $135M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
PRNewsWire·Nov 11, 2026
Telix to Participate in UBS Global Biopharma Conference

/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") will participate in the upcoming UBS Global Biopharma Conference in London (UK)

GlobeNewsWire·Nov 5, 2026
Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth

Gross margin reaches 78%; cash used in operating activities declines 56% sequentially Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year remains at 70% or higher New Cook Medical agreement positions TULSA-PRO ® within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach across the United States Richard Fabian appointed as CEO, effective January 14, 2027; Arun Menawat to transition to Executive Chairman; Matthew Sobczyk becomes permanent CFO; Jason Mills joins Board TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the third quarter ended September 30, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).

MarketBeat·Nov 4, 2026
Telix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy Push

Telix Pharmaceuticals NASDAQ: TLX outlined its commercial growth strategy, late-stage radiopharmaceutical pipeline and planned integration of ITM at an investor event in Melbourne, with management emphasizing supply-chain control, therapeutic expansion and a target to transition toward earnings growth beginning in 2028.

Seeking Alpha·Oct 23, 2026
Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case

Telix Pharmaceuticals maintains a buy rating, driven by robust 3Q26 performance and the strategic ITM acquisition to diversify revenue and strengthen isotope supply. 3Q26 revenue rose 19% YoY to $245 million, with Precision Medicine up 30% YoY; Pixclara approval and pipeline advancements offer additional growth catalysts. The ITM acquisition, valued at $1.65 billion with up to $700 million in contingent payments, is expected to deliver $50 million in synergies and meaningful EBITDA from 2027.

Filtered for Telix Pharmaceuticals LimitedMore Headlines
04

Compare before deciding

Benchmark TLX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Telix Pharmaceuticals Limited (TLX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
TLX logoTLXTelix Pharmaceuticals LimitedCurrent
$8.86$3B-427.780.84%-0.89%-1.42%—
EXEL logoEXELExelixis, Inc.
$68.50$17.22B19.796.98%35.45%45.54%—
RNW logoRNWReNew Energy Global Plc
$6.95$2.53B18.9943.31%8.5%8.46%—
AGEN logoAGENAgenus Inc.
$6.21$258.6M18.4110.37%20.98%——
LNTH logoLNTHLantheus Holdings, Inc.
$101.80$6.63B25.800.5%17.28%21.72%—
NVS logoNVSNovartis AG
$159.13$302.46B30.215.97%17.82%24.32%2.53%

Compare TLX vs Peers

Telix Pharmaceuticals Limited (TLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs EXEL

Most directly comparable listed peer for TLX.

Scale Benchmark

vs GE

Larger-name benchmark to compare TLX against a more recognizable public peer.

Peer Set

Compare Top 5

vs EXEL, RNW, AGEN, LNTH

Get notified when TLX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

TLX Frequently Asked Questions

Telix Pharmaceuticals Limited (TLX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Telix Pharmaceuticals Limited's revenue?

Telix Pharmaceuticals Limited (TLX) reported $789.8M in revenue in fiscal year 2025.

How fast is Telix Pharmaceuticals Limited growing?

Telix Pharmaceuticals Limited (TLX) grew revenue by 0.8% in fiscal year 2025, compared with the prior fiscal year.

Is TLX profitable?

No. Telix Pharmaceuticals Limited (TLX) reported a net loss of $7.0M in fiscal year 2025.

Dividend & Returns
What is TLX's return on equity?

Telix Pharmaceuticals Limited (TLX) had a return on equity (ROE) of -1.4% in fiscal year 2025. A negative ROE means the company lost money over the period.

What is Telix Pharmaceuticals Limited's free cash flow?

Telix Pharmaceuticals Limited (TLX) had negative free cash flow of $54.2M in fiscal year 2025.

What if you invested $1,000 in TLX back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →